Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($) $ in Thousands	Total	February 28, 2023	August 25, 2023	Standby Equity Purchase Agreement	Commitment To Issue Registered Shares	Notes Payable	Cumulative Effect, Period of Adoption, Adjustment	Additional Paid-in Capital	Additional Paid-in Capital February 28, 2023	Additional Paid-in Capital August 25, 2023	Additional Paid-in Capital Standby Equity Purchase Agreement	Additional Paid-in Capital Commitment To Issue Registered Shares	Additional Paid-in Capital Notes Payable	Accumulated Other Comprehensive Gain (Loss)	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment	Class A Common Stock	Class A Common Stock Commitment To Issue Registered Shares	Class A Common Stock Cumulative Effect, Period of Adoption, Adjustment	Class A Common Stock Common Stock	Class A Common Stock Common Stock Standby Equity Purchase Agreement	Class A Common Stock Common Stock Commitment To Issue Registered Shares	Class A Common Stock Common Stock Notes Payable	Class B Common Stock Common Stock
Beginning balance (in shares) at Dec. 31, 2021																	0
Beginning balance at Dec. 31, 2021																	$ 0
Beginning balance (Accounting Standards Update 2020-06) at Dec. 31, 2021																			$ 32,900
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance pursuant to commitment to issue registered shares																		$ (32,900)
Ending balance (in shares) at Dec. 31, 2022																	0
Ending balance at Dec. 31, 2022																	$ 0
Beginning Balance (in shares) at Dec. 31, 2021																				702,887				0
Beginning Balance at Dec. 31, 2021	$ 567,655							$ 3,482,244						$ (6,945)	$ (2,907,644)					$ 0				$ 0
Beginning Balance (Accounting Standards Update 2020-06) at Dec. 31, 2021							$ (20,265)									$ (20,265)
Beginning Balance (Accounting Standards Update 2016-02) at Dec. 31, 2021							$ 3,393									$ 3,393
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of convertible securities (in shares)																	1,071,008
Conversion of notes payable into Class A Common Stock (Note 7)	164,068							164,068
Reclassification of earnout shares from equity to liability on April 21, 2023 due to insufficient authorized shares (Note 10)	(4,000)
Issuance of Common Stock (in shares)																				371,468	3,288	9,948		266,670
Issuance of Common Stock	0			$ 252	$ 32,900						$ 252	$ 32,900
Stock-based compensation	17,664							17,664
Chongqing related party note payable restructuring (Note 8)	16,841							16,841
Exercise of stock options and settlement on restricted stock tax withholding (in shares)																				17,084
Exercise of stock options and settlement on restricted stock tax withholding	9,015							9,015
Exercise of warrants (in shares)																				121,261
Exercise of warrants	7,419							7,419
Amended exercise price of ATW NPA warrants (Note 11)	1,238							1,238
Transfer of private warrants to unaffiliated parties	264							264
Repurchase and retirement of Class A Common Stock (in shares)																				(404)
Repurchase and retirement of Class A Common Stock	(767)							(767)
Receipt of class A common stock in consideration of exercises of options (in shares)																				(1,300)
Receipt of Class A Common Stock in consideration of exercises of options	(669)							(669)
Issuance of shares for RSU vesting net of tax withholdings (in shares)																				52,036
Liability for insufficient authorized shares related to stock options and RSUs	(3,977)							(3,977)
Liability for insufficient authorized shares related to earnout	(2,250)							(2,250)
Foreign currency translation adjustment	10,450													10,450
Net loss	(602,239)														(602,239)
Ending Balance (in shares) at Dec. 31, 2022																				2,347,276				266,670
Ending Balance at Dec. 31, 2022	200,992							3,724,242						3,505	(3,526,755)					$ 0				$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of convertible securities (in shares)																							25,025,903
Conversion of notes payable into Class A Common Stock (Note 7)						$ 360,668							$ 360,665							$ 3
Change in classification of warrants from Additional paid-in capital to liability pursuant to the Warrant Exchange (Note 7)	(6,811)							(6,811)
Reclassification of stock-based awards liability to equity due to authorized share increase		$ 8,978	$ 2,043						$ 8,978	$ 2,043
Reclassification of earnout shares from equity to liability on April 21, 2023 due to insufficient authorized shares (Note 10)	(2,112)							(2,112)
Reclassification of stock-based awards from equity to liability on April 21, 2023 due to insufficient authorized shares (Note 10)	(2,979)							(2,979)
Issuance of Common Stock (in shares)																				14,752,057
Issuance of Common Stock	34,492							34,491												$ 1
Reverse Stock split related round up share issuances (in shares)																				81,560
Stock-based compensation	5,101							5,101
Cancellations (in shares)																				(1,031)
Exercise of stock options and settlement on restricted stock tax withholding (in shares)																				207
Exercise of stock options and settlement on restricted stock tax withholding	$ 44							44
Exercise of warrants (in shares)	251,649																			213,037
Exercise of warrants	$ 51,276							51,276
Issuance of shares for RSU vesting net of tax withholdings (in shares)																				14,016
Issuance of shares for RSU vesting net of tax withholdings	(464)							(464)
Liability for insufficient authorized shares related to earnout		$ 5,014	$ 1,381						$ 5,014	$ 1,381
Foreign currency translation adjustment	2,357													2,357
Net loss	(431,744)														(431,744)
Ending Balance (in shares) at Dec. 31, 2023																				42,433,025				266,670
Ending Balance at Dec. 31, 2023	$ 228,236							$ 4,180,869						$ 5,862	$ (3,958,499)					$ 4				$ 0